Literature DB >> 18611973

Insulin-like factor 3 levels in second-trimester amniotic fluid.

Katrine Bay1, Arieh S Cohen, Finn Stener Jørgensen, Connie Jørgensen, Anne Marie Lind, Niels E Skakkebaek, Anna-Maria Andersson.   

Abstract

BACKGROUND: According to animal studies, the testicular Leydig cell hormone insulin-like factor 3 (Insl3) exerts a fundamental role in abdominal testis translocation, which occurs in the beginning of the second trimester in humans. Despite this, human prenatal INSL3 production has been poorly investigated.
METHODS: Amniotic fluid from 91 pregnant women undergoing amniocentesis was analyzed for INSL3 and testosterone (T) levels. Data were related to gestational age (15-25 wk) at amniocentesis and to sex (45 males and 48 females).
RESULTS: INSL3 was present in amniotic fluid from all but one of the investigated male fetuses (range: <0.02-0.36 ng/ml; mean +/- sd: 0.12 +/- 0.07), whereas the hormone was undetectable in the female fetuses. T was significantly higher in male (range: 0.54-1.71 nmol/liter; mean +/- sd: 1.04 +/- 0.30) as compared with in female amniotic fluid (range: 0.19-0.50 nmol/liter; mean +/- sd: 0.34 +/- 0.06) (P < 0.001). In males there was no correlation between INSL3 and T. A statistically borderline negative association was found between INSL3 and gestational age (P = 0.07), whereas the corresponding association was not significant for T (P = 0.12). In contrast, T in females correlated positively with gestational age (P = 0.02).
CONCLUSIONS: INSL3 is clearly present in human male amniotic fluid in the second trimester, where abdominal testis translocation takes place. In contrast, the hormone is undetectable in female amniotic fluid. The prenatal presence of INSL3 supports the hypothesis that this hormone is essential for testicular descent in humans.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18611973     DOI: 10.1210/jc.2008-0358

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

1.  Serum insulin-like factor 3 quantification by LC-MS/MS in male patients with hypogonadotropic hypogonadism and Klinefelter syndrome.

Authors:  Trine Holm Johannsen; Marie Lindhardt Ljubicic; Jacques Young; Séverine Trabado; Jørgen Holm Petersen; Allan Linneberg; Jakob Albrethsen; Anders Juul
Journal:  Endocrine       Date:  2021-01-22       Impact factor: 3.633

Review 2.  Testicular descent: INSL3, testosterone, genes and the intrauterine milieu.

Authors:  Katrine Bay; Katharina M Main; Jorma Toppari; Niels E Skakkebæk
Journal:  Nat Rev Urol       Date:  2011-03-15       Impact factor: 14.432

3.  Clinical aspects of histological and hormonal parameters in boys with cryptorchidism: Thesis for PhD degree.

Authors:  Simone Engmann Hildorf
Journal:  APMIS       Date:  2022-07       Impact factor: 3.428

4.  Diverse functions of insulin-like 3 peptide.

Authors:  Maria Esteban-Lopez; Alexander I Agoulnik
Journal:  J Endocrinol       Date:  2020-10-01       Impact factor: 4.286

5.  Insulin-Like Peptide 3 (INSL3) Serum Concentration During Human Male Fetal Life.

Authors:  Steven M Harrison; Nicol Corbin Bush; Yi Wang; Zachary R Mucher; Armando J Lorenzo; Gwen M Grimsby; Bruce J Schlomer; Erika E Büllesbach; Linda A Baker
Journal:  Front Endocrinol (Lausanne)       Date:  2019-09-04       Impact factor: 5.555

6.  Amniotic Fluid INSL3 Measured During the Critical Time Window in Human Pregnancy Relates to Cryptorchidism, Hypospadias, and Phthalate Load: A Large Case-Control Study.

Authors:  Ravinder Anand-Ivell; Arieh Cohen; Bent Nørgaard-Pedersen; Bo A G Jönsson; Jens-Peter Bonde; David M Hougaard; Christian H Lindh; Gunnar Toft; Morten S Lindhard; Richard Ivell
Journal:  Front Physiol       Date:  2018-04-24       Impact factor: 4.566

Review 7.  Fertility of Cryptorchid Testis-An Unsolved Mistery.

Authors:  Carmen Iulia Ciongradi; Ioan Sârbu; Codruța Olimpiada Iliescu Halițchi; Diana Benchia; Klara Sârbu
Journal:  Genes (Basel)       Date:  2021-11-26       Impact factor: 4.096

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.